Expert Ratings For Blueprint Medicines
Portfolio Pulse from Benzinga Insights
In the last three months, 17 analysts have evaluated Blueprint Medicines (NASDAQ:BPMC), showing a range of sentiments from bullish to bearish. The average 12-month price target has increased by 14.52% to $116.35. Analysts have recently raised their price targets, reflecting positive market sentiment. Blueprint Medicines has shown strong financial performance with significant revenue growth, high net margin, and effective debt management.
June 28, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Blueprint Medicines (NASDAQ:BPMC) has received mixed analyst ratings over the past three months, with a notable increase in the average 12-month price target by 14.52% to $116.35. Recent analyst actions have predominantly been positive, with several raising their price targets. The company's strong financial performance, including a 51.87% revenue growth rate and high net margin, supports a positive outlook.
The increase in the average price target and the positive financial performance indicators such as revenue growth, net margin, ROE, and ROA suggest a bullish short-term impact on BPMC's stock price. The majority of recent analyst actions have been positive, further supporting this outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100